Allergy Therapeutics (LON:AGY) chief executive Manuel Llobet said: “It’s been quite a good year, we have progressed on all of our strategic goals, namely progressing on our businesses in Europe.”
Allergy Therapeutics said the global allergy treatment market had seen some “turmoil” affecting the competitive market environment in Europe and the US, but the group said it would likely see mid to long-term benefits in terms of its US market share.
“We are building a nice, thriving, sound company in the European market,” says Llobet, but focus remains the US.
“The biggest opportunity we want to tap is the US, that’s our focus,” he says.
The group plans to add two or three new markets a year to expand its portfolio franchise.